Therapeutic Efficacy: A Prerequisite for Novel Intermediates- Delhi High Court ruling in Zeria Pharmaceutical Co. Ltd. v. the Controller of Patents

The Delhi High Court dismissed Zeria Pharmaceutical Co. Ltd.’s (the ‘Appellant’) appeal against the Controller of Patents' (the ‘Respondent’) refusal order of a divisional patent application (3630/DLNP/2011). The ruling focused on a novel intermediate compound rejected for lack of inventive step and for failing to demonstrate enhanced therapeutic efficacy. Case Background  Zeria filed a divisional […]